PAREXEL Launches Next Generation Analytics Capabilities within Perceptive MyTrials® Platform

Enhancements offer clients cross-study oversight through mobile-enabled reporting and analysis 

BOSTON, MA— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials® platform with advanced analytics capabilities.  With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously.  The solution offers real-time and aggregated analytics allowing sponsors and PAREXEL® clinical research professionals to detect key signals and trends.  The Perceptive MyTrials Analytics solution also offers cross-sponsor viewing options for clients who need to evaluate data from multiple sponsors.

"As clinical studies become more complex, there is a growing need for real-time and standardized data and analytics from multiple studies," said Xavier Flinois, President, PAREXEL Informatics.  "Using the enhanced tools available with the Perceptive MyTrials Analytics solution, our clients can visualize trends across studies, garner reliable intelligence, and confidently make data-driven business decisions. This information will ultimately help reduce risk, increase clinical trial efficiency, and speed time to market for our clients and for patients."

Developed by PAREXEL Informatics, the Perceptive MyTrials® platform provides an integrated suite of applications for managing clinical trials.  Perceptive MyTrials Analytics offers enhanced analytics capabilities and cross-study business intelligence from within the Perceptive MyTrials platform.

Flinois added, "At PAREXEL, our mission is to bring science to the real world by simplifying a client's journey at every step.  Perceptive MyTrials Analytics is another example of the integrated solutions we are developing that incorporate optimized study management processes that leverage mobile and analytics as part of our broader 'SMAC' [social media, mobile, analytics, and cloud] technology approach."

Perceptive MyTrials® Analytics is available directly as part of PAREXEL clinical research services or via the Perceptive® Partner Program.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of expertise-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics, Inc. provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 80 locations in 51 countries around the world, and had approximately 17,440 employees in the third quarter.  For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL, PAREXEL Informatics, Perceptive, and Perceptive MyTrials are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates.  All other trademarks are the property of their respective owners.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "should,"  "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ materially from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses including the acquisitions of ClinIntel Limited and Quantum Solutions India, or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of foreign currency exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 as filed with the Securities and Exchange Commission on May 1, 2015, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.